14 generics are evaluated for consistency.

On October 19th, the official website of the State Drug Administration showed that the following 14 drugs had recently passed/as if they had passed a consistent evaluation.
Among them, Zhengda Qing Kapeta bin tablets, four-ring pharmaceutical gaba spray capsules are the 3rd in China, Fuyuan Medicine Reglinai tablets, Hengrui Pharmaceuticals hydrochloric acid Prakso slow release tablets, Renheyikang hydrochloric acid Sinacase tablets are the second in China, Chifeng Wanze Pharmaceuticals Arkmos ointment is the first in the country.
the following selected part of the drug for a brief introduction: Capertabin tablet Capedabin is a chemotherapy drug, originally developed by Roche, in April 1998 in the United States was approved, in March 2001, Roche Capabin tablets in China was approved for import, the commodity named Hiroda.
capabin tablets for the country's third batch of drugs, after the consistent evaluation of Hengrui and Qilu Pharmaceuticals have been successful bid.
reglenay tablets, reglinai is a new type of non-sulfonylcean short-acting oral insulin-promoting sugar-lowering drug.
the variety in 2017 domestic sales of about 1.1 billion yuan, the current domestic manufacturers are No. 1 and Nord, Bei lu pharmaceutical, Fuyuan Pharmaceuticals, Conrey Pharmaceuticals and Howson Pharmaceuticals 5, but previously only Haussen Pharmaceuticals through a consistent evaluation.
Plaxo hydrochloric acid prakso slow release tablet is a Parkinson's treatment drug, the original manufacturer for Grigg Ingham.
currently approved in China' Prakso dosage forms are mainly tablets and slow release tablets.
, slow release tablets have been the first to be approved by Beijing-New Pharmaceuticals, and as if through a consistent evaluation.
Sinecase hydrochloric acid Senaccaser tablets hydrochloric acid is mainly used to treat secondary thyroid hyperthyroidism in patients with chronic kidney disease (CKD) maintenance dialysis, which is a common complication in CKD patients, and is also one of the most important and serious complications in the end-stage hemodialysis of chronic kidney failure.
April 15th, jiayi Pharmaceuticals, a subsidiary of Yanyuan Pharmaceuticals, obtained the approval of the State Drug Administration for the first copy of the hydrochloric acid synacaser tablets, and was evaluated as consistent.
Ren Heyikang was approved this time, for the second domestic drug approved manufacturers, as if through the consistent evaluation.
Tekmos ointment Tekmos ointment is mainly used for the treatment of moderate to severe special dermatitis, the drug previously had 7 domestic manufacturers, Chifeng Wanze Pharmaceuticals Takmos ointment according to the new 4 categories approved for listing, approved as follows by consistent evaluation, for the first domestic drug evaluation manufacturers.
.